SinoBiom Group was founded in 2007 by a globally respected polymer scientist, supported by a team of internationally renowned chemists and physicists. The Group specializes in large-scale production of ultrahigh-performance bioactive polylactic acid for medical applications, built on core capabilities in controlled polymerization and multifactor polymer physical modification. Its product portfolio spans a comprehensive range of clinical fields—including orthopedics, trauma surgery, sports medicine, neurosurgery, and plastic surgery—reflecting the depth of its scientific foundation. With a team of over 1,000 employees, including multiple academicians, doctoral and postdoctoral researchers, SinoBiom Group possesses strong technological innovation and translational capabilities.

SinoBiom Group New R&D and Manufacturing Campus
The completion of the new campus lays a solid foundation for SinoBiom Group's development in the coming decade. As an ultra-high-performance medical device industrial park, it spans 110,000 m² of facilities, including a 68,000 m² production area equipped with GMP-standard production lines, advanced R&D and testing systems, and large-scale manufacturing capabilities for significant capacity expansion—enabling the mass production of medical-grade polymer materials at an unprecedented level.

Through the dedicated efforts of its team, SinoBiom Group has grown into a respected enterprise in the biomedical materials and medical device industry. The Group has been recognized with key national-level credentials, including the International Technological Cooperation Base and the National Postdoctoral Entrepreneurship Base. During its development, SinoBiom has undertaken numerous major government science and technology projects and has actively participated in international cooperation programs, national talent introduction initiatives, and national innovation fund projects.

On a global scale, SinoBiom Group stands alone as the only company with a fully integrated platform spanning the entire journey—from processing medical-grade polylactic acid raw materials to developing biodegradable implants. Rooted in deep expertise in regenerative biomaterials, the Group is committed to the vision of creating inherently safe, bioabsorbable solutions that restore the body’s own capacity for renewal, exemplifying the philosophy of a true bioactivator rather than a mere biostimulator.